Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Female Libido Drug, Addyi, Shows Modest Results

By Drug Discovery Trends Editor | March 1, 2016

Allen G. Breed/APAbout six months ago, in a historical and controversial move, the Food and Drug Administration approved flibanserin (Addyi), the first prescription drug designed to boost a women’s libido. The drug’s approval was considered a victory for a lobbying campaign that has argued for gender equality, while a coalition of health providers contended that flibanserin works minimally better than a placebo and has substantially harmful side effects.

On Monday, researchers reported follow-up results: The drug is said to increase satisfying sexual encounters by close to one a month, on average.

In the new study, published in JAMA Internal Medicine, researchers found that benefits were slightly more modest than those submitted to the FDA during the approval process. The findings came from a first pooled analysis of five published and three unpublished clinical trials, of nearly 6,000 women. Treatment with flibanserin, they concluded, resulted in “one-half of an additional sexually satisfying encounter per month.” (The study did not define what “one-half” of a sexually satisfying encounter was).

When the drug was submitted to the FDA for approval last year, it was based on original findings from three clinical trials that found that women taking flibanserin had an average of about one additional satisfying sexual encounter a month, in addition to the two to three they were already having. “That result lifted the benefits above the bar of being scientifically meaningful, but barely,” wrote The New York Times. “Still, it was enough for the agency’s approval.”

Flibanserin was approved last June, after twice being rejected by the FDA. The drug from Sprout Pharmaceuticals aims to increase women’s sex drive by altering brain chemistry.

Side effects of the drug include sleepiness, dizziness, fatigue and nausea, and these increase with alcohol consumption.

In June, Sprout said it will not advertise on radio or television for 18 months after the drug’s approval and instead, focus its marketing on doctors, not consumers.

The study authors wrote in JAMA Internal Medicine: “With nearly 90 percent of American physicians indicating that they would prescribe an approved hypoactive sexual desire disorder pharmacological product over available nonpharmacological treatments, the need for sound evidence on the efficacy and safety profile of flibanserin is evident.

“The findings of this review suggest that the benefits of flibanserin treatments are marginal…Before flibanserin can be recommended in guidelines and clinical practice, future studies should include women from diverse populations, particularly women with a history of somatic and psychological comorbidities, medication use, and surgical menopause.”

In a commentary published alongside the study, Dr. Steven Woloshin and Dr. Lisa M. Schwartz, professors at Dartmouth Medical School wrote, “The flibanserin saga is unsatisfying. The FDA approved a marginally effective drug for a non-life-threatening condition in the face of substantial — and unnecessary — certainty about its dangers. Women with distressing sexual desire problems need good treatments. We all need a drug approval process that delivers good decisions based on adequate evidence.”


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE